Accessibility StatementSkip Navigation Novo Nordisk Amended Proposal Values Metsera at up to $ 86.20 per Share, a Total of Approximately $ 10.0 Billion Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders Superior to Revised Pfizer Proposal that Valued Metsera at up to $ 70.00 per Share, a Total of Approximately $ 8.1 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments for Two Business Days NEW YORK, Nov. 4, 2025 /PRNewswire/ - ...

TESLA WATCH: Elon Musk Pay Deal In FocusPfizer (PFE) stock slipped early Tuesday after the S&P 500 pharma titan reported adjusted income of 87 cents per share on $16.65 billion in third-quarter sales.On average, analysts polled by FactSet expected Pfizer to earn 63 cents per share on $16.51 billion in sales.During the year-earlier period, Pfizer earned $1.06 a share and reported $17.7 billion in sales.For the year, Pfizer reaffirmed its sales guidance for $61 billion to $64 billion, but raised and narrowed ...

Market Analysis by covering: Gold Spot US Dollar, Pfizer Inc, US Dollar Index Futures, S&P 500 Futures. Read 's Market Analysis on Investing.com ...

智通财经APP获悉，辉瑞(PFE.US)公布了好于预期的2025年第三季度业绩，同时上调了全年盈利预期。该公司表示，持续推进的成本削减措施 帮助弥补了销售增长放缓带来的压力，这也为其竞购减肥药初创公司Metsera(MTSR.US)提供了资金支持。 财报显示，辉瑞Q3营收同比下降6%至166.54亿美元，好于分析师普遍预期的165亿美元;调整后的净利润为49.49亿美元，同比下降18%;调整后的 每股收益为0.87美元，好于分析师普遍预期的0.64美元。 | ($ in millions, except per share | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | amounts) | Third-Quarter | | | | Nine Months | | | | 2025 | 2024 | % Change | 2025 | 2024 | % Change | | Revenues | $ 16,654 | $ 17,702 | (6%) | $ 45,022 | $ 45,864 | (2%) | | Reported(3) ...

Skip to content S&P 500 6,791.80 -1.03% Dow Jones 47,085.60 -0.57% Nasdaq 100 25,649.20 -1.39% Russell 2000 2,441.33 -1.45% FTSE 100 9,660.60 -0.55% Nikkei 225 51,378.70 -2.19% Home >Investing >Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (November 2025) Shares of Pfizer (NYSE: PFE)Â lost 9.90% over the past month after gaining 10.02% the month prior. The stock's year-to-date loss now stands at 7.33%. Over the past year, PFE has fallen by 11.17%. The recent rally in the Big Pharma stock c ...

辉瑞Q3营收166.5亿美元，同比下降6%，主要受新冠产品需求下滑拖累。辉瑞预计全年调整后每股收益3-3.15美元，此前预计2.9-3.1美元，因其非新冠 业务增长抵消整体营收滑坡。 辉瑞Q3营收由去年同期的177亿美元降至166.5亿美元，同比下降6%，主要受新冠产品（Paxlovid和Comirnaty）需求下滑拖累。尽管如此，公司上调 了其全年盈利预测，因其非新冠业务增长抵消整体营收滑坡。 公司在财报中宣布，与特朗普政府达成一项历史性协议，通过直接采购平台提供大幅折扣，换取关税豁免和长期业务的确定性。然而，其进军利润丰厚 的减肥药市场的雄心正面临挑战，在一项关键的收购交易中，辉瑞已针对竞争对手诺和诺德和目标公司Metsera提起诉讼。 4日，辉瑞公布Q3财报： 按业务划分： 第三季度营收166.5亿美元，同比下降6%（运营层面下降7%），市场预估165.9亿美元。 净利润为35.41亿美元，同比下降21%；调整后净利润为49.49亿美元，下降18%。 调整后每股收益0.87美元，同比增长18%，超出市场预期。 全球生物制药业务（Biopharma）第三季度营收163.1亿美元，同比下降6%； Pfize ...

盘前市场动向 1. 11月4日(周二)美股盘前，美股三大股指期货齐跌。截至发稿，道指期货跌0.63%，标普500指数期货跌0.99%，纳指期货跌 1.28%。 | = US 30 | 47,039.20 | 47,360.40 | 46,852.60 | -298.10 | -0.63% | | --- | --- | --- | --- | --- | --- | | = US 500 | 6,784.10 | 6,855.20 | 6,757.80 | -67.90 | -0.99% | | 트 US Tech 100 | 25,640.60 | 25,970.10 | 25,517.00 | -332.30 | -1.28% | 2. 截至发稿，德国DAX指数跌1.25%，英国富时100指数跌0.59%，法国CAC40指数跌1.19%，欧洲斯托克50指数跌1.07%。 | 德国DAX30 | 23,809.33 | 23,845.33 | 23,670.00 | -301.10 | -1.25% | | --- | --- | --- | --- | --- | --- | | 瑞 英国富时100 | ...

Pfizer reported lower third-quarter profit as demand for its Covid-19 vaccine and antiviral drug continue to decline. ...

格隆汇11月4日｜辉瑞(PFE.US)盘前涨超2%。消息面上，辉瑞第三季度营收166.5亿美元，预估165.9亿 美元；调整后每股收益0.87美元。辉瑞仍然预测全年营收610亿美元至640亿美元。预计全年调整后每股 收益3-3.15美元，此前预计2.9-3.1美元。 ...

Exhibit 99 Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance NEW YORK, Tuesday, November 4, 2025 — Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising and narrowing guidance for Adjusted diluted EPS. (1) (2) EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "I am proud of Pfizer's leadership as the first in our industry to reach an agreement with the U.S. Government, whic ...